Eli Lilly to acquire AtaiBeckley for up to $3.8 billion as Big Pharma embraces psychedelic drugs for mental health.
Eli Lilly is set to acquire AtaiBeckley for up to $3.8 billion, signaling a major shift in the pharmaceutical industry toward psychedelic medications. The acquisition highlights the growing validation of these drugs as viable alternatives for treating mental health conditions, particularly treatment-resistant depression. AtaiBeckley’s lead asset, BPL-003, is a synthetic form of 5-MeO-DMT administered as a nasal spray. It has shown rapid and durable results in Phase 2b trials for patients who do not respond to standard treatments. This move follows an executive order from the administration in April to fast-track the review of such drugs by the Food and Drug Administration. While the market is expanding, analysts note that success depends on clinical maturity and "short-duration" assets that reduce the burden of care. Other major players, including AbbVie and Otsuka Pharmaceuticals, have also made significant investments in the sector. With 23.4% of U.S. adults experiencing mental illness, the administration's push for psychedelic integration offers a significant opportunity for new therapeutic models.